Skip to main content

Sonoma Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

SNOA$1.14+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three Months ended June 30, 2024 and 2023

(In thousands, except share amounts)

Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive
SharesAmountCapitalDeficitLossTotal
Balance, March 31, 202415,607,433$2$203,207$(194,349)$(2,723)$6,137
Proceeds from At-the-Market sale of common stock, net of offering expenses3,166,202–748––748
Proceeds from exercise of employee stock options40,000–7––7
Employee stock-based compensation expenses190,758–107––107
Foreign currency translation adjustment––––(881)(881)
Net loss–––(1,143)–(1,143)
Balance, June 30, 202419,004,393$2$204,069$(195,492)$(3,604)$4,975
Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive
SharesAmountCapitalDeficitLossTotal
Balance, March 31, 20234,933,550$5$200,904$(189,514)$(3,418)$7,977
Cost in connection with ATM––(5)––(5)
Employee stock-based compensation expenses208,046–177––177
Foreign currency translation adjustment––––511511
Net loss–––(1,418)–(1,418)
Balance, June 30, 20235,141,596$5$201,076$(190,932)$(2,907)$7,242
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.